Kenvue Inc. remains a closely watched consumer health name as investors weigh trusted brands, improving margins and a major pending transaction. In the first quarter of 2026, adjusted gross margin expanded 80 basis points to 60.8% and adjusted operating margin improved 420 basis points to 24%, driven by supply-chain productivity and cost optimization actions. Skin Health and Beauty net sales increased 8.4%, with organic sales up 5%, supported by volume growth and innovation such as Neutrogena's entry into sun care in select EMEA markets. The pending cash-and-stock combination with Kimberly-Clark Corporation, under which Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash per Kenvue share, has received shareholder approvals and U.S. antitrust clearance, with closing expected in the second half of 2026. The stock currently carries a Zacks Rank #3 (Hold), with Value, Growth and VGM Scores of C and a Momentum Score of D, reflecting a balanced near-term view.
Kenvue Inc.Improved margins (gross +80bps, operating +420bps) and pending acquisition by Kimberly-Clark with shareholder and antitrust approvals.
Kimberly-Clark CorporationPending combination with Kenvue is a strategic M&A transaction that expands Kimberly-Clark's consumer health portfolio.
Procter & Gamble Company